Health Care Compliance Association's (HCCA) West Coast Regional Annual Conference
27 June 2008
Foley Partners Shirley Morrigan and Cheryl Wagonhurst will be speaking at the Health Care Compliance Association’s (HCCA) West Coast Regional Annual Conference, June 27, 2008 in Los Angeles, California.
Ms. Morrigan is speaking from 10:15 a.m. – 11:15 a.m. Her session is titled: “Key California Health Laws of Interest to the Compliance Officer.” Topics that will be covered include:
- AB 632 Medical Staff Whistleblower Protection
- AB 682 Changes in Consent Requirements for HIV/AIDS Testing
- A potpourri of other legislation related to compliance
Ms. Wagonhurst is speaking from 3:45 p.m. – 4:45 p.m. with Rory Jaffe, Executive Director – Medical Services, Office of the President, University of California. Their session is titled “Quality of Care and Compliance.” Topics that will be covered include:
- How to integrate quality into your compliance program
- Recently issued OIG/AHLA guidance for Boards of Directors
- When to consider using outside independent review organizations when peer review is not working
People
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”